arrow
D

Domenico Mallardo

istituto nazionale tumori irccs fondazione g pascale
H指数:25
被引数:3,426

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune Checkpoint Inhibitor Data in Metastatic Melanoma with Pre-Existing Autoimmune Disease: A Real World Experience

免疫检查点抑制剂在伴有预存自身免疫性疾病转移性黑色素瘤中的数据:一项真实世界研究

2026-10-030
OA
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study

体重指数和血清肌酐水平的组合可预测接受纳武利尤单抗治疗的霍奇金淋巴瘤患者的生存情况(CheckMate 205研究)

2025-06-010
OA
Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy

液体活检中的代谢组学特征与接受免疫检查点抑制剂治疗的转移性黑色素瘤患者的总生存期相关

2025-04-100
OA
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
2024-08-012
OA
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
2024-01-020
OAAI
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
2023-10-255
OAAI
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
2023-09-0814
OAAI
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

癌症患者的2型糖尿病和免疫检查点阻断的疗效结果

2023-06-0125
OA
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
2023-02-239
OAAI
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

转移性黑色素瘤患者的Nivolumab血清浓度可能与预后和增强的免疫活性有关: 基因分析回顾性分析

2022-11-245
OAAI
IL-6 AS PROGNOSTIC FACTOR IN ADJUVANT OR METASTATIC SKIN CANCER PATIENTS TREATED WITH IMMUNOTHERAPY - A REAL LIFE STUDY
2022-11-070
OA